Spots Global Cancer Trial Database for Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Official Title: A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
Study ID: NCT04609566
Study Description
Brief Summary: This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
Highlands Oncology Group, Springdale, Arkansas, United States
cCARE - Northern, Fresno, California, United States
The Angeles Clinic and Research Institute, Los Angeles, California, United States
Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
California Cancer Associates for Research and Excellence Inc (cCARE), San Marcos, California, United States
University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States
Rocky Mountain Cancer Centers - Aurora, Denver, Colorado, United States
Memorial Healthcare System, Hollywood, Florida, United States
Memorial Healthcare System, Pembroke Pines, Florida, United States
Affiliated Oncologists, LLC, Chicago Ridge, Illinois, United States
Northwestern University, Chicago, Illinois, United States
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
University of Kansas Cancer Center, Kansas City, Kansas, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Henry Ford Health System, Detroit, Michigan, United States
Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
New York Oncology Hematology, P.C., Clifton Park, New York, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
Toledo Clinic Cancer Center, Toledo, Ohio, United States
Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
Texas Oncology - Austin Central, Austin, Texas, United States
Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States
Texas Oncology - Fort Worth 12th Avenue, Fort Worth, Texas, United States
Oncology Consultants, PA, Houston, Texas, United States
Inova Schar Cancer Institute, Fairfax, Virginia, United States
Virginia Oncology Associates, Norfolk, Virginia, United States
Virginia Commonwealth University Medical Center, Richmond, Virginia, United States
Oncology and Hematology Associates of Southwest Virginia, Roanoke, Virginia, United States
Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States
University of Ottawa / Ottawa General Hospital, Ottawa, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
McGill University Department of Oncology / McGill University Health Centre, Montreal, Quebec, Canada
Contact Details
Name: Medical Monitor
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
